// App-Quantinova.ai

1033 : Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).

Researchers

Presenter

  • David B. Page

Principal Investigators

  • Isaac K Kim

  • Katherine Sanchez

  • Nicole Moxon

  • Staci L. Mellinger

  • Alison Katherine Conlin

  • Anupama Kurup Acheson

  • Kelly Shea Perlewitz

  • Stacy K. Lewis

  • Kathleen A. Kemmer

  • Zahi Ibrahim Mitri

  • Reva K Basho

  • Emily Riffle

  • Jenny Ahn

  • Joanna Pucilowska

  • Maritza Martel

  • Walter John Urba

  • Heather L. McArthur

Medical Centers

  • Earle A. Chiles Research Institute, Portalnd, OR

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • Providence Cancer Center, Portland, OR

  • Hematology and Oncology Clinic, Portland, OR

  • Providence Cancer Center Oncology and Hematology Care Clinic, Portland, OR

  • Providence Oncology and Hematology Care Clinic, Newberg, OR

  • Providence Onc, Portland, OR

  • Oregon Health and Science University, Portland, OR

  • Cedars-Sinai Medical Center, Houston, TX

  • Cedar-Sinai, Los Angeles, CA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR

  • Providence Medical Center, Portland, OR

  • Cedars-Sinai Medical Center, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • T-cell receptor

Drug/Treatment

  • Pembrolizumab

  • Capecitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Simon'S Two Stage Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02734290

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved